BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8

• Press Releases

  Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

  July 2, 2025

   · 

  7 min read
• Press Releases

  Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

  July 2, 2025

   · 

  4 min read
• Press Releases

  Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

  July 2, 2025

   · 

  8 min read
• Press Releases

  Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

  July 2, 2025

   · 

  6 min read
• Press Releases

  Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

  July 2, 2025

   · 

  3 min read
• Press Releases

  BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

  July 2, 2025

   · 

  11 min read
• Press Releases

  Bio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan Africa

  July 2, 2025

   · 

  3 min read
• Press Releases

  Adagene announces up to $25 million strategic investment from Sanofi

  July 2, 2025

   · 

  5 min read
• Press Releases

  Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

  July 2, 2025

   · 

  4 min read
• Press Releases

  There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

  July 2, 2025

   · 

  10 min read